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Abstract 
Background: The sensitivity of rapid diagnostic tests (RDTs) for malaria is inadequate for detecting low‑density, often 
asymptomatic infections, such as those that can occur when screening pregnant women for malaria. The perfor‑
mance of the Alere™ Ultra‑sensitive Malaria Ag Plasmodium falciparum RDT (uRDT) was assessed retrospectively in 
pregnant women in Indonesia.
Methods: The diagnostic performance of the uRDT and the CareStart™ Malaria HRP2/pLDH VOM (Plasmodium vivax, 
Plasmodium ovale and Plasmodium malariae) Combo RDT (csRDT) were assessed using 270 stored red blood cell pel‑
lets and plasma samples from asymptomatic pregnant women. These included 112 P. falciparum negative and 158 
P. falciparum positive samples detected by a composite test (qPCR, LAMP, nPCR) as reference standard. Diagnostic 
indicators: sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV), diagnostic odds ratio 
(DOR) and the level of agreement (kappa) were calculated for comparison.
Results: Compared with the reference test, the uRDT had a sensitivity of 19.6% (95% CI 13.9–26.8) and specificity of 
98.2% (93.1–99.7%). The csRDT was 22.8% (16.7–30.3) sensitive and 95.5% (89.4–98.3) specific for P. falciparum infec‑
tions. Performance of the uRDT was non‑significantly different to the csRDT (p = 0.169). RDT outcome was stratified by 
qPCR cycling threshold (Ct), and performance of the RDTs was found to be comparable across parasite loads.
Conclusion: The uRDT performed similarly to the currently used csRDTs in detecting P. falciparum infections in 
asymptomatic pregnant women. In these settings, molecular diagnostics are currently the most sensitive for malaria.
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Background
Control programmes for malaria will need to account for 
the changing epidemiology of malaria as countries pro-
gress toward elimination. The current goal to eliminate 
malaria in 31 countries by 2030 will require sensitive 
diagnostic tools [1] to detect the reservoir of low-den-
sity and often sub-patent infections [2–5]. Although the 
infectivity of these asymptomatic individuals is low, mod-
elling shows that they contribute significantly to onward 
transmission because they make up the majority of the 
population in low-transmission areas [4, 6].
Diagnosis of malaria during pregnancy is complicated 
by the ability of certain Plasmodium falciparum para-
sites to sequester in the placenta, which can result in 
parasite densities in the peripheral blood below the level 
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of detection of existing Rapid Diagnostic Tests (RDTs) 
and light microscopy [7–11]. Diagnosis and treatment 
of these infections may improve pregnancy outcomes 
[12, 13] by preventing them from developing into pat-
ent infections and may control transmission by reduc-
ing the parasite reservoir [3, 8, 12, 13]. Lateral-flow rapid 
diagnostic tests detecting circulating malaria antigen 
are simple, widely used, and the cheapest point-of-care 
diagnostic tool for malaria. Many countries in the Asia–
Pacific region use “Test and Treat” strategies at the first 
antenatal booking visit to screen all pregnant women for 
malaria regardless of symptoms [14–16], or are explor-
ing intermittent screening and treatment (IST) strategies 
to test women at each scheduled antenatal visit [13, 17]. 
However, the current generation of standard RDTs for 
malaria has a limit of detection of 100 parasites/µl and is 
not designed to detect low-density infections in asymp-
tomatic pregnant women [2]. Low-cost and field-deploy-
able highly sensitive rapid diagnostics may improve the 
detection of malaria in these populations. [2, 18].
Currently, only nucleic acid amplification tests 
(NAATs) are sufficiently sensitive to detect these low-
density infections [2]. However, these methods are lim-
ited to well-equipped laboratory settings due to their 
inherent complexity and need for laboratory equipment.
Recently, the new Alere™ Ultra-sensitive Malaria Ag 
P. falciparum RDT (uRDT) was developed to bridge the 
gap between high-sensitivity and field-ready diagnostics 
[19]. To date, studies in Uganda, Ethiopia, Myanmar and 
Papua New Guinea have shown superior sensitivity of the 
uRDT in comparison to widely used SD Bioline RDTs in 
asymptomatic general population. An additional labo-
ratory study reports a log-fold lower limit of detection 
(LOD) for the HRP2 antigen (80 pg/ml) [19]. The only 
study in pregnant women did not observe notable differ-
ences in sensitivity between the uRDT and existing SD 
Bioline RDTs. [20].
This study describes the performance of the uRDT and 
standard RDT CareStart™ Malaria HRP2/pLDH Pf/VOM 
Combo (csRDT) in stored blood specimens of asympto-
matic pregnant women in Indonesia compared to a com-
posite molecular tests.
Methods
Study sites and sample collection
The study was performed using stored samples of red 
blood cell pellets (pRBC) reconstituted with plasma 
collected during a recently completed STOPMIP trial 
(ISRCTN: 34010937) comparing intermittent preven-
tive treatment or intermittent screening and treatment 
strategies with single screen and treatment in preg-
nant women in Indonesia [17]. The trial was conducted 
between 2013 and 2016 in Timika in Mimika District 
southern Papua-Indonesia, an area with moderate, year-
round malaria transmission [21]. All four major species 
of Plasmodium are endemic in the area with P. falcipa-
rum accounting for 57.9% of infections, Plasmodium 
vivax—33.8%, Plasmodium malariae—4.4% and Plasmo-
dium ovale—0.5% amongst pregnant women [21]. Co-
infections of P. falciparum and P. vivax account for the 
remaining 3.8%.
Whole blood samples were taken from asymptomatic 
pregnant women (> 16 weeks gestation) at antenatal 
visits to screen for malaria infection. During the trial 
this included microscopy, molecular malaria diagnos-
tics (qPCR), nested PCR (nPCR), and loop-mediated 
isothermal amplification (LAMP). Malaria RDTs (First 
Response Malaria Ag pLDH–HRP2 Combo [I16FRC30]; 
Premier Medical Corporation, Nani Daman, India) were 
also done at enrolment in the single-screen and treat and 
intermittent screen and treat arms of the STOPMIP trial. 
The FirstResponse RDT data is not included in this study 
as the number of matched samples was low.
Sample processing
During STOPMIP trial, venous blood (4 ml) was col-
lected from each participant in EDTA tubes at the 
booking and delivery visits and processed within 24 h. 
Samples were centrifuged for 10 min at 15,000 rpm and 
RBCs and plasma separated and stored at − 20 °C. Dried 
blood spots (DBS) were also prepared at the field labo-
ratory, where 10 µl blood was pipetted on to filter paper 
(Whatman 3MM) and left to air-dry, stored in zip-lock 
bags and transported to the Eijkman institute of molecu-
lar biology for molecular testing.
RDTs
The RDTs used here recommend using whole blood 
samples. Due to storage conditions in the trial pellets of 
frozen RBCs were first reconstituted by adding the cor-
responding plasma sample to a final haematocrit (HCT) 
of 30%. This reflects the average haemoglobin level (~ 11 
g/dL) observed previously in this population [18, 22] 
and in STOPMiP participants [17]. The Alere™ Ultra-
sensitive Malaria Ag P. falciparum RDT (uRDT, Stand-
ard Diagnostic Inc. Suwon City, South Korea, Catalogue 
No: 05FK140, Lot No. 05LDC002A) detects P. falcipa-
rum infections only. The CareStart RDT (csRDT) (Car-
eStart™ Malaria HRP2/pLDH Pf/VOM Combo RDT, 
Catalogue No: G0171, Lot No. RMR17H111, Access Bio, 
USA) detects P. falciparum and non-falciparum para-
sites (P. vivax, P. ovale and P. malariae). With both RDTs, 
the presence of a line in the ‘C’ window indicated a valid 
test. Invalid tests were repeated. A valid uRDT test was 
determined positive if a line was observed in the P. fal-
ciparum-line (Pf-line) window, whilst a valid csRDT was 
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determined positive if the Pf-line was present regardless 
of presence or absence of a line in the Pvom window.
Both RDTs were performed according to the manu-
facturer’s protocol: briefly, a five µl reconstituted blood 
sample was added to the RDT cassette, followed by three 
(csRDT) or four (uRDT) buffer drops. RDTs were read 
according to the manufacturer’s guidelines; after 20 min 
for uRDTs and 15 min for csRDTs. RDTs were performed 
at the Eijkman Institute by an operator who was blinded 
to the reference test results. Presence of a line on a RDT 
was confirmed by two independent operators. A third 
operator was consulted in case of uncertainty, and the 
test was declared positive if two operators agreed.
Reference standard: composite molecular test
Molecular testing was carried out on DNA extracted 
(Chelex method) in 2016–2017 from DBS samples. 
Briefly, 6 mm filter paper punches were incubated on 
0.5% saponin overnight, before centrifugation and dis-
card of supernatant. Following rigorous PBS washing, 
the DBS was heated in 20% Chelex 100-Ion Exchanger 
for 10 min (Biorad Laboratories, Hercules, CA) at 100 °C, 
and the remaining supernatant stored at − 20 °C [17].
LAMP and qPCR results formed a composite molecu-
lar reference. Discordant results underwent nested PCR 
testing as the gold standard, which was run in triplicate 
and results were determined positive if a single replicate 
was positive by nPCR. These composite molecular tests 
were used as the reference standard (further described by 
Ahmed et al. [17]).
Nested PCR was performed on LAMP-positive/qPCR 
negative samples with primers and cycling conditions 
described in Singh et al. [23]. The nPCR was used as the 
gold standard whereby a single positive result determined 
the sample as positive for P. falciparum. The LOD of this 
assay is ~ 6 parasites/μl [23].
LAMP assays were carried out using the Loopamp™ 
Malaria Pan Detection Kit (Eiken Chemical Company, 
Japan). Briefly, the LAMP reagents were reconstituted 
with 15 μl water/tube and left to stand for 2 min, before 
adding 15 μl of extracted DNA. Samples were incubated 
for 40  min at 65  °C and then 5  min at 80  °C. Results 
were interpreted under a UV light, where a green col-
our change indicated a positive result.
For qPCR, reactions contained, 2 μl DNA, QuantiFast 
Pathogen PCR Mix (Qiagen™, Hilden, Germany) and 
primers and probes published by Kamau et al. for P. fal-
ciparum and P. vivax identification [24], whilst P. ovale 
and P. malariae primers and probes are published by 
Shokoples et al. see Table 1 [25]. Thermocycling condi-
tions (38 cycles) were as follows: 10 min at 95 °C, 15 s 
for 95 °C and 60 s for 60 °C. Fluorescence was acquired 
using the Rotor-Gene Q 5plex HRM Platform (Qia-
gen™, Hilden, Germany) and cycle threshold (Ct) values 
were calculated using the Rotorgene Q series software 
version 1.7 (Qiagen Inc, Valencia, CA, USA). The LOD 
of this LAMP and qPCR assays is 2–5 parasite/μl.
All molecular testing was carried out by independent 
operators blinded to clinical information. The LAMP, 
qPCR and nPCR were carried out a year prior to testing 
with the uRDT and csRDT. LAMP, csRDT and uRDT 
tests were carried out at the Eijkman Institute, Jakarta, 
Indonesia and qPCR testing was subsequently carried 
out at the Liverpool School of Tropical Medicine, UK.
Positive DNA controls for each species (provided by 
the Malaria Reference Laboratory, Public Health Eng-
land) and negative controls were included in every 
molecular assay run. All assays were carried out by 
independent operators blinded to clinical information. 
Index testing was also carried out without knowledge 
of the reference standard results.
Table 1 Working concentrations and sources are provided for the qPCR primers and probes. Table adapted from Ahmed 
et al. [17]
Sequence 5′–3′ Concentration (nM) Source
Pan reverse [25] AAC CCA AAG ACT TTG ATT TCT CAT AA 200 Eurofins
MAL FP [25] CCG ACT AGG TGT TGG ATG ATA GAG TAAA 50 Eurofins
MAL probe [25] ATTO700‑CTA TCT AAA AGA AAC ACT CAT‑MGBEDQ 80 Eurogentec
OVA FP [25] CCG ACT AGG TTT TGG ATG AAA GAT TTTT 50 Eurofins
OVA Probe [25] Cy5‑CGA AAG GAA TTT TCT TAT T‑MGBEDQ 80 Eurogentec
FAL FP [24] ATT GCT TTT GAG AGG TTT TGT TAC TTT 400 Eurofins
FAL RP [24] GCT GTA GTA TTC AAA CAC AAT GAA CTCAA 400 Eurofins
FAL probe [24] FAM‑CAT AAC AGA CGG GTA GTC AT‑MGBQ 200 Thermo
VIV FP [24] GCA ACG CTT CTA GCT TAA TCCAC 400 Eurofins
VIV RP [24] CAA GCC GAA GCA AAG AAA GTCC 400 Eurofins
VIV probe [24] VIC‑ACT TTG TGC GCA TTT TGC TA‑MGBQ 200 Thermo
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Sample size
The sample size was calculated using G*Power software 
v3.1.9.2 (University of Dusseldorf, Germany). Estimat-
ing a proportion of 0.35 discordant results between the 
two RDTs (based on previously published data in simi-
lar transmission setting [26]), a sample size of 120 posi-
tive samples was estimated to provide sensitivity with 
80% statistical power and 99% confidence intervals. 
Studies have shown both uRDT and csRDT have simi-
larly high specificity (> 96%) [18, 19, 26]. Therefore, the 
sample size was estimated to be able to detect differ-
ences only in sensitivity. The final sample size (n = 270) 
used for this analysis were those samples with sufficient 
volumes of both plasma and pRBCs remaining for RDT 
testing. Of these, 158 were P. falciparum positive and 
112 negatives by the composite molecular reference 
test.
Statistical analysis
Diagnostic accuracy was estimated by calculating the 
total number of true positives (TP), false positives (FP), 
true negatives (TN), false negatives (FN), sensitivity and 
specificity (%), positive predictive value (PPV) and neg-
ative predictive value (NPV). PPV and NPV calculated 
according to prevalence within the sample collection. 
The reference test method to get the TP, FP, TN and FN 
was the composite molecular test results (LAMP, qPCR 
and nPCR). Agreement between either RDT and the 
composite reference test was calculated by determining 
the kappa value (k). Kappa values < 0.2 were considered 
a poor agreement, 0.21–0.40 fair, 0.41–0.6 moder-
ate, 0.61–0.8 very good [18]. The diagnostic odds ratio 
(DOR) was calculated as the ratio of the odds of posi-
tivity in those with malaria (defined by molecular com-
posite reference test) relative to the odds of positivity 
in those without malaria). The Ct values were used as a 
proxy of parasite densities. The significance of the dif-
ference observed between the uRDT and csRDT  R2 cor-
relation coefficients was assessed using a Fisher r-to-z 
transformation. The analysis was conducted using SPSS 
(version 24.0, Armonk, New York) and an online calcu-
lator [27, 28] which uses the efficient-score method to 
calculate 95% confidence intervals.
Ethical approval
Ethical clearance was obtained from the Liverpool 
School of Tropical Medicine and the Eijkman Insti-
tute for Molecular Biology, Jakarta, Indonesia. Written 
informed consent was obtained.
Results
In total, 270 samples were screened. These included 
158 P. falciparum positive samples (including non-fal-
ciparum Plasmodium co-infections) and 112 negative 
samples (by molecular composite). Only 23 positive 
samples were detected by either uRDT and csRDT 
(Fig. 1).
Agreement with reference test
The level of agreement of either RDT with the reference 
test was poor: uRDT; kappa value = 0.15 (95% CI 0.09–
0.21), csRDT; kappa = 0.16 (0.09–0.23) (Table  2). The 
uRDT detected 31 (19.6%) infections confirmed by the 
reference test, of which 23 (74.0%) were also detected by 
the csRDT (Fig. 1). The uRDT missed 13 (36%) infections 
that were detected by the csRDT and confirmed by the 
reference test. The uRDT detected eight infections that 
were not detected by csRDT (Fig. 1).
Diagnostic performance
The sensitivities compared with the reference test were 
19.6%, (95% CI 13.9–26.8) for the uRDT and 22.8%, 
(16.7–30.3) for the csRDT. Both tests showed high speci-
ficity (> 95%). The uRDT DOR was 13.4 (3.1–57.4) and 
the csRDT 6.3 (2.4–16.7). (Table 2) When comparing the 
overall performance of the uRDT and csRDT, the differ-
ence in proportions detected was non-significantly differ-
ent (p = 0.169).
Fig. 1 Venn diagram showing the number of P. falciparum positive 
samples detected by each test. Positivity by uRDT, csRDT and the 
composite molecular reference test (Ref.Std) in 270 samples from 
asymptomatic pregnant women. Numbers within the circles (n) 
indicate the number of true positives detected by that test
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Parasite density distribution
The qPCR Ct value was used as a proxy for parasite 
density. Overall, 36% of qPCR positives fell between Ct 
33–35 (reflecting an estimated 1–10  parasites/µl), and 
nearing the reported uRDT LOD of 3.13  p/μl [19], and 
25% fell below Ct 30, the estimated LOD of the csRDT 
LOD (~ 100  parasites/μl) [19]. There was no evidence 
that the relative performance of the RDTs was modified 
by CT value (p = 0.3) (Fig. 2).
Exclusion of co‑infections
Considering the uRDT only detects P. falciparum infec-
tions, the effects of co-infections with P. vivax were also 
assessed. When P. falciparum-negative/P. vivax-positive 
samples were excluded from the data set, the number of 
false positives detected only by the csRDT was reduced 
(from 5 to 3), thus increasing the specificity and PPV. 
This resulted in a near doubling of the csRDT DOR (12.1; 
2.8–51.6), while the performance of the uRDT remained 
relatively unchanged. Again, the difference in propor-
tions detected by each test was not different from each 
other (n = 238, p = 0.4, Table 2).
Discussion
This study shows that in a moderate transmission setting 
in Indonesia, amongst asymptomatic pregnant women, 
the uRDT performed similarly to the csRDTs, which is a 
widely used test in the malaria in pregnancy control pro-
gramme in Indonesia.
These results are supported by a study in Colombia, 
which also used stored samples from pregnant women. 
Although they note a trend of increased sensitivity by the 
uRDT, it was not found to be significantly different from 
the Standard Bioline RDT (sdRDT) [20]. A Tanzanian 
study in febrile children and adult outpatients also found 
no difference between uRDT and sdRDT performance, 
although febrile patients tend to have higher parasitaemia 
[29]. The results here differ from other studies conducted 
in non-pregnant populations that showed a significant 
increase in sensitivity of the uRDT compared to cur-
rent RDTs. [19, 26, 30, 31]. The most apparent difference 
between the conflicting results is the target population 
(pregnant vs non-pregnant) and the storage conditions. 
It would be useful to screen pregnant populations in the 
same settings where differences in RDT performance 
were observed. One such study has commenced in Papua 
New Guinea (personal communications with Dr Leanne 
Robinson).
The uRDT is an antigen capture test specific to the P. 
falciparum HRP2 antigen, whereas the csRDT captures 
pLDH specific to P. vivax, P. ovale and P. malariae (indi-
cated by the VOM window), in addition to PfHRP2 (Pf 
window). Ahmed et  al. showed that amongst pregnant 
women in Indonesia, when using a different CareStart 
RDT that captures both pan-LDH and PfHRP2, reading 
the PfHRP2 window alone was less sensitive than using in 
combination with the pLDH results [18]. These findings 
and the low sensitivity of both RDTs demonstrated here, 
may point towards low HRP2 concentrations that fall 
below the limit of either RDT (uRDT LOD = 80  pg/ml, 
csRDT = 200 pg/ml). Low concentrations of HRP2 could 
be due to low parasitaemia, degradation of the protein 
during storage or deletions in the gene for this protein.
The sample set included a total of 8 samples that were 
P. falciparum-positive by the FirstResponse RDT per-
formed during the trial (2014–2016), 6 of which were 
also positive by microscopy. All of these samples were 
also positive using the uRDT and CareStart in this study. 
This suggests minimal degradation over the storage 
period (1–3 years).
The non-linear relationship between HRP2 con-
centration/persistence and parasite density [19, 26], 
complicates analyses between RDT positivity and para-
sitaemia. Although no trend in sensitivity was observed 
with increasing Ct values (indicative of parasitaemia), 
however, most samples fell above Ct 30 indicating very 
low parasitaemias. Finally, HRP2 deletions have been 
reported in P. falciparum from several countries in South 
America, Africa and also India [32–34], but not yet in 
SE. Asia. As yet, no full deletions (only polymorphisms 
Fig. 2 Diagnostic performance stratified by qPCR Ct values. The bar 
chart shows the sensitivity of each test: uRDT (grey) and csRDT (white 
bar and black trendline) stratified by qPCR cycle‑threshold (Ct) values. 
The number of qPCR‑ positive samples in each Ct category is given 
in brackets (n). Trendlines (dashed) are derived from the rolling mean 
sensitivity calculated for every 10 observations. R squared coefficient 
values are displayed (uRDT; grey text, csRDT; black text) and difference 
between  R2 values is non‑significant (n.s, p = 0.3 one‑tailed t‑test). 
(28) Error bars represent upper and lower 95% CI
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[35]) of HRP2 have been reported in Indonesia, although 
this is an area for further consideration. HRP2 mutations 
have been implicated in the poor sensitivity of RDTs [33]. 
Early laboratory analyses of the uRDT using cultured 
parasites with HRP mutations demonstrated that the 
uRDT performance varies considerably depending on 
mutations of the HRP protein [19]. Consequently, inves-
tigations around HRP2 polymorphisms in this sample set 
are underway.
A limitation of this study is the use of different sample 
types used for the molecular and RDT testing. Molecular 
testing used stored DNA extracted from DBS, whereas 
RDTs were performed using pRBC and plasma samples 
reconstituted to an artificial HCT of 30%. Potential deg-
radation of HRP2 in the stored samples could contribute 
to poor sensitivity of both RDTs since RDT testing was 
carried out 1 year after molecular testing, although posi-
tive samples remained positive over this time. The sen-
sitivity of the molecular testing could also be enhanced 
through targeting higher copy genes [36] or RNA [37], 
or by using improved extraction methods [38]. The per-
formance of both RDTs is anticipated to improve using 
fresh whole blood at point of contact, i.e. for the intended 
user scenario. However, the low sensitivity observed here 
is similar to reported sensitivities using a range of alter-
native RDTs in pregnant women in Indonesia. [18] The 
important finding here is that the uRDT performed simi-
larly to the csRDT.
Conclusion
The diagnostic performance of the uRDT was assessed in 
a diagnostically challenging population: asymptomatic, 
pregnant women in a moderate transmission setting 
in Indonesia. This is the first study testing the uRDT in 
pregnant women in Asia and will build evidence to guide 
policy around the implementation of this test in these 
populations. In comparison to the composite molecular 
reference tests, both the uRDT and csRDT showed low 
sensitivity. Given the negative outcomes associated with 
malaria in pregnancy, it is crucial to detect and treat 
these infections rapidly. Further work is needed to assess 
the diagnostic performance of the uRDT in pregnant 
women before consideration of this test for implementa-
tion where csRDT are already being used- particularly in 
asymptomatic pregnant women in moderate transmis-
sion settings.
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